TG Therapeutics, Inc. Announces First Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Tomorrow, Tuesday

TG Therapeutics, Inc. Announces First Quarter 2015 Financial

Results and Business Update

Investor Conference Call to be Held Tomorrow, Tuesday, May

5, 2015 at 8:00am EDT

New York, NY, (May 4, 2015) - TG Therapeutics,

Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2015 and recent company developments.

Michael S. Weiss, the Company's Executive Chairman and Interim

Chief Executive Officer, stated, "During the first quarter, we focused on site initiation and enrollment into our GENUINE

Phase 3 clinical trial, as well as the continued enrollment into our Phase 1/2 trial of our proprietary combination of TG-1101

and TGR-1202, also referred to as 1303, and we look forward to presenting updated data from these studies next month. During the

quarter we were also excited to continue to add to our pipeline with the in-licensing of our anti-PD-L1 and anti-GITR antibody

research programs." Mr. Weiss continued, "Finally, we took advantage of continued favorable market conditions to bolster

our balance sheet, ending the quarter with over $110 million in cash on a pro forma basis, positioning us well to execute on our

aggressive business plan."

Recent Developments and Upcoming Events

Reaffirming 2015 Milestones

Financial Results for the First Quarter 2015

At March 31, 2015 the Company had cash, cash equivalents, investment

securities, and interest receivable of $105.2 million, which includes approximately $34.2

million of net proceeds from the utilization of the Company's at-the-market ("ATM")

sales facility during the first quarter, as compared to $78.9 million at December 31, 2014.

Pro-forma cash, cash equivalents, investment securities, and

interest receivable as of March 31, 2015 are approximately $113.2 million, including $8.0 million of net proceeds from the utilization

of the ATM sales facility during the second quarter of 2015.

Our consolidated net loss for the first quarter ended March

31, 2015, excluding non-cash items, was approximately $9.2 million, which included approximately $4.3 million of manufacturing

and CMC expenses in preparation for Phase 3 clinical trials and commercialization. The consolidated net loss for the first quarter

ended March 31, 2015, inclusive of non-cash items, was $14.6 million, or $0.39 per diluted share, compared to a consolidated net

loss of $7.5 million during the comparable quarter in 2014, representing an increase in consolidated net loss of $7.1 million.

The increase in consolidated net loss during the first quarter ended March 31, 2015 was primarily the result of other research

and development expenses for TG-1101 and TGR-1202 increasing approximately $4.1 million and $1.1 million, respectively, over the

comparable period in 2014. The increase in other research and development expenses related to TG-1101 was primarily the result

of increased manufacturing and clinical trial expenses in preparation for the launch of Phase 3 registration programs. Also contributing

to the increase in consolidated net loss during the quarter ended March 31, 2015 was a $1.1 million increase in non-cash compensation

expense related to equity incentive grants.

Conference Call Information

The Company will host an investor conference call tomorrow,

Tuesday, May 5, 2015, at 8:00am EDT, to discuss the Company's first quarter 2015 financial results and provide a business

outlook for the remainder of 2015.

In order to participate in the conference call, please call

1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2015 Earnings Call. A

live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the

Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com,

for a period of 30 days after the call.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the

acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently,

the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered

monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics

is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells

of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202

are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop

IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered

Cautionary Statement

Some of the statements included in this press release, particularly

those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects

for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements

that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking

statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results

to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials

for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical

and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1

and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which

underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory

safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that

the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical

and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project

over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to

time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release

speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect

events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com.

The information found on our website is not incorporated by reference into this press release and is included for reference purposes

Director- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: ir@tgtxinc.com

TG Therapeutics, Inc.

Selected Consolidated Financial Data

of Operations Information (Unaudited):

Balance Sheet Information: